Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy

Fertility and Sterility

Volumn 92, Issue 3, 2009, Pages 1018-1024

  Pickar, James H ^a   Yeh, I Tien ^b   Bachmann, Gloria ^c   Speroff, Leon ^d  

^a PFIZER INC   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

B azedoxifene; conjugated estrogens; endometrium; hyperplasia; tissue selective estrogen complex; TSEC

Indexed keywords

BAZEDOXIFENE; CONJUGATED ESTROGEN; PLACEBO; RALOXIFENE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG SAFETY; ENDOMETRIAL DISEASE; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MULTICENTER STUDY; OVARY CYST; PHASE 3 CLINICAL TRIAL; POLYP; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVICITIS; UTERINE CERVIX DISEASE; UTERINE CERVIX DYSPLASIA;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INDOLES; MIDDLE AGED; OUTPATIENTS; POSTMENOPAUSE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME;

EID: 69049085452     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.05.094     Document Type: Article

References (16)

1. Smith D.C., Prentice R., Thompson D.J., and Herrmann W.L. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293 (1975) 1164-1167
2. Ziel H.K., and Finkle W.D. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 293 (1975) 1167-1170
3. Woodruff J.D., and Pickar J.H. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol 170 (1994) 1213-1223
4. Stovall D.W., Utian W., Gass M., Qu Y., Muram D., Wong M., et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 14 (2007) 510-517
5. Davis S.R., O'Neill S.M., Eden J., Baber R., Ekangaki A., Stocks J.M., et al. Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium-a pilot study. Menopause 11 (2004) 167-175
6. Komm B.S., and Lyttle C.R. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci 949 (2001) 317-326
7. Komm B.S., Kharode Y.P., Bodine P.V., Harris H.A., Miller C.P., and Lyttle C.R. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 146 (2005) 3999-4008
8. Ronkin S., Northington R., Baracat E., Nunes M.G., Archer D.F., Constantine G., et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 105 (2005) 1397-1404
9. Crabtree J.S., Peano B.J., Zhang X., Komm B.S., Winneker R.C., and Harris H.A. Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland. Mol Cell Endocrinol 287 (2008) 40-46
10. Kurman R.J., and Norris H.J. Endometrial hyperplasia and related cellular changes. In: Kurman R.J. (Ed). Blaustein's pathology of the female genital tract (1994), Springer-Verlag, New York 411-437
11. Pickar J.H., Yeh I., Wheeler J.E., Cunnane M.F., and Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 76 (2001) 25-31
12. Pickar J.H., Yeh I.T., Wheeler J.E., Cunnane M.F., and Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril 80 (2003) 1234-1240
13. Anderson G.L., Judd H.L., Kaunitz A.M., Barad D.H., Beresford S.A., Pettinger M., et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. J Am Med Assoc 290 (2003) 1739-1748
14. Lobo R.A., Pinkerton J.V., Gass M.L.S., et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 92 (2009) 1025-1038
15. Lindsay R., Gallagher J.C., Kagan R., Pickar J.H., and Constantine G. Efficacy of tissue-selective estrogen complex (TSEC) of bazedoxifene/conjugated estrogens (BZA/CE) for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 92 (2009) 1045-1052
16. Archer D.F., Lewis V., Carr B.R., Olivier S., and Pickar J.H. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 92 (2009) 1039-1044